Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13609557 | 0.87 | CYP1A2 (0.64) | CYP1A2CYP2C19MAPK1TSHRGAA | |
| SCHEMBL13609506 | 0.85 | CYP1A2 (0.49) | CYP1A2CYP2C19MAPK1TSHRGAA | |
| SCHEMBL13609546 | 0.82 | MAPK1 (0.69) | MAPK1TSHRGAASMN1; SMN2NPC1 | |
| SCHEMBL13621662 | 0.82 | CSNK2A2 (0.42) | CYP1A2CYP2C19MAPK1TSHRGAA | |
| SCHEMBL4255385 | 0.81 | L3MBTL1 (0.54) | CYP1A2CYP2C19MAPK1TSHRGAA | |
| SCHEMBL4259414 | 0.79 | CSNK2A2 (0.46) | CYP1A2CYP2C19MAPK1TSHRGAA | |
| SCHEMBL10085276 | 0.78 | MAPK1 (0.50) | CYP1A2CYP2C19MAPK1TSHRGAA | |
| SCHEMBL13609562 | 0.77 | MAPK1 (0.42) | CYP1A2CYP2C19MAPK1TSHRGAA | |
| SCHEMBL13609551 | 0.76 | TSHR (0.42) | CYP1A2CYP2C19MAPK1TSHRGAA | |
| SCHEMBL9386914 | 0.75 | GAA (0.57) | CYP1A2CYP2C19MAPK1TSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281142-A1 | THIAZOLE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281142-A1 | THIAZOLE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| CN-101228143-A | Thiazole derivatives | ASTELLAS PHARMA INC (JP) | 2008-07-23 | — | — | CN | disclosed |
| EP-1921074-A1 | THIAZOLE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281142-A1 | THIAZOLE DERIVATIVE | GK, GCKR, AK2 | CYP1A2 2841/4885CYP2C19 3703/4885MAPK1 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.